VOYA INVESTMENT MANAGEMENT LLC - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
VOYA INVESTMENT MANAGEMENT LLC ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$196,235
-42.4%
17,568
+10.3%
0.00%
Q2 2023$340,881
-45.9%
15,929
+2.2%
0.00%
-100.0%
Q1 2023$630,298
-13.1%
15,5860.0%0.00%0.0%
Q4 2022$725,061
-10.3%
15,5860.0%0.00%0.0%
Q3 2022$808,446
+9.4%
15,586
-0.3%
0.00%
-50.0%
Q2 2022$739,000
-33.6%
15,6370.0%0.00%0.0%
Q1 2022$1,113,000
-1.4%
15,637
+3.6%
0.00%0.0%
Q4 2021$1,129,000
+55.9%
15,099
+18.6%
0.00%
+100.0%
Q3 2021$724,000
+30.7%
12,733
+1.1%
0.00%0.0%
Q2 2021$554,000
-15.3%
12,595
-5.0%
0.00%0.0%
Q1 2021$654,000
+20.4%
13,251
+2.6%
0.00%0.0%
Q4 2020$543,000
+5.4%
12,909
+14.7%
0.00%0.0%
Q3 2020$515,000
-9.6%
11,250
-0.8%
0.00%0.0%
Q2 2020$570,000
-16.9%
11,343
-14.9%
0.00%
-50.0%
Q1 2020$686,000
-14.4%
13,330
+2.8%
0.00%0.0%
Q4 2019$801,000
+13.8%
12,968
+10.6%
0.00%0.0%
Q3 2019$704,000
-29.0%
11,720
-0.3%
0.00%0.0%
Q2 2019$992,000
-11.8%
11,760
-0.2%
0.00%
-33.3%
Q1 2019$1,125,000
+31.6%
11,780
-2.4%
0.00%
+50.0%
Q4 2018$855,000
+10.2%
12,075
+32.9%
0.00%0.0%
Q3 2018$776,000
+0.5%
9,086
+36.5%
0.00%0.0%
Q2 2018$772,000
+34.0%
6,657
-6.5%
0.00%
+100.0%
Q1 2018$576,000
+29.7%
7,119
-5.8%
0.00%0.0%
Q4 2017$444,000
+13.6%
7,558
-9.5%
0.00%0.0%
Q3 2017$391,000
+30.3%
8,3500.0%0.00%0.0%
Q2 2017$300,000
+32.2%
8,350
+13.3%
0.00%0.0%
Q1 2017$227,000
-72.4%
7,373
-70.0%
0.00%
-50.0%
Q4 2016$823,000
-29.7%
24,576
-44.1%
0.00%0.0%
Q3 2016$1,170,000
+73.8%
43,962
+44.1%
0.00%0.0%
Q2 2016$673,000
-24.9%
30,5110.0%0.00%0.0%
Q1 2016$896,000
-24.6%
30,511
-15.2%
0.00%
-33.3%
Q4 2015$1,188,000
-92.4%
35,991
-91.7%
0.00%
-92.3%
Q3 2015$15,714,000
-6.1%
434,802
+16.9%
0.04%
+2.6%
Q2 2015$16,735,000
+6121.2%
371,998
+6932.1%
0.04%
+3700.0%
Q4 2014$269,000
+28.7%
5,2900.0%0.00%
Q3 2014$209,000
-8.3%
5,2900.0%0.00%
-100.0%
Q2 2014$228,0005,2900.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 858,811$36,156,00010.56%
Fairmount Funds Management LLC 150,433$6,333,0002.26%
ARMISTICE CAPITAL, LLC 1,356,000$57,088,0001.94%
FARALLON CAPITAL MANAGEMENT LLC 1,775,000$74,728,0000.45%
Virtus ETF Advisers LLC 14,321$603,0000.25%
Granahan Investment Management 231,071$9,728,0000.22%
JACOBS LEVY EQUITY MANAGEMENT, INC 248,320$10,454,0000.09%
ACADIAN ASSET MANAGEMENT LLC 467,514$19,684,0000.08%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 126$5,0000.08%
AIGEN INVESTMENT MANAGEMENT, LP 12,854$541,0000.07%
View complete list of ENANTA PHARMACEUTICALS INC shareholders